- Home
- AKAM vs GMAB Comparison
AKAM vs GMAB Comparison
Compare AKAM & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAM
- GMAB
- Stock Information
- Founded
- AKAM 1998
- GMAB 1999
- Country
- AKAM United States
- GMAB Denmark
- Employees
- AKAM N/A
- GMAB N/A
- Industry
- AKAM Business Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AKAM Consumer Discretionary
- GMAB Health Care
- Exchange
- AKAM Nasdaq
- GMAB Nasdaq
- Market Cap
- AKAM 11.4B
- GMAB 13.2B
- IPO Year
- AKAM 1999
- GMAB N/A
- Fundamental
- Price
- AKAM $77.64
- GMAB $24.65
- Analyst Decision
- AKAM Hold
- GMAB Buy
- Analyst Count
- AKAM 17
- GMAB 6
- Target Price
- AKAM $95.56
- GMAB $37.60
- AVG Volume (30 Days)
- AKAM 2.3M
- GMAB 1.2M
- Earning Date
- AKAM 08-07-2025
- GMAB 08-07-2025
- Dividend Yield
- AKAM N/A
- GMAB N/A
- EPS Growth
- AKAM N/A
- GMAB 77.72
- EPS
- AKAM 2.82
- GMAB 21.62
- Revenue
- AKAM $4,083,251,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- AKAM $5.48
- GMAB $21.64
- Revenue Next Year
- AKAM $5.23
- GMAB $15.57
- P/E Ratio
- AKAM $27.52
- GMAB $11.06
- Revenue Growth
- AKAM 3.98
- GMAB 32.97
- 52 Week Low
- AKAM $67.51
- GMAB $17.24
- 52 Week High
- AKAM $106.80
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- AKAM 55.71
- GMAB 67.82
- Support Level
- AKAM $74.86
- GMAB $21.00
- Resistance Level
- AKAM $76.65
- GMAB $22.90
- Average True Range (ATR)
- AKAM 2.20
- GMAB 0.43
- MACD
- AKAM 0.50
- GMAB 0.24
- Stochastic Oscillator
- AKAM 89.83
- GMAB 95.31
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.